Pelthos Therapeutics Inc. (PTHS): R&D Expense
$1.23M
Year ended 2025-12-31
+46.4%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.23M | +4.2% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $1.18M | -54.3% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $2.58M | +558.5% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $391.7K | n/a | 2024-04-16, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $261.38M | -18.1% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $18.67M | -37.4% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Alector, Inc. (ALEC) | 2025-12-31 | $123.06M | -33.8% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $94.43M | -13.5% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $109.44M | -15.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $114.15M | +6.3% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $1.87M | -52.4% |
Compare PTHS, RLAY, LENZ, LCTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗